Literature DB >> 25261094

Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia.

Simone Thomas1, Roland Schelker2, Sebastian Klobuch2, Sascha Zaiss2, Martina Troppmann2, Michael Rehli2, Torsten Haferlach3, Wolfgang Herr2, Albrecht Reichle2.   

Abstract

Entities:  

Keywords:  5-azacytidine; ATRA; acute myeloid leukemia; biomodulatory therapy; pioglitazone

Mesh：

Substances：

Year:  2014        PMID： 25261094      PMCID： PMC4281320          DOI： 10.3324/haematol.2014.115055

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.

Authors:  N Curik; P Burda; K Vargova; V Pospisil; M Belickova; P Vlckova; F Savvulidi; E Necas; H Hajkova; C Haskovec; J Cermak; M Krivjanska; M Trneny; P Laslo; A Jonasova; T Stopka
Journal:  Leukemia       Date:  2012-02-20       Impact factor: 11.528

2.  Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program.

Authors:  Luca Maurillo; Adriano Venditti; Alessandra Spagnoli; Gianluca Gaidano; Dario Ferrero; Esther Oliva; Monia Lunghi; Alfonso M D'Arco; Alessandro Levis; Domenico Pastore; Nicola Di Renzo; Alberto Santagostino; Vincenzo Pavone; Francesco Buccisano; Pellegrino Musto
Journal:  Cancer       Date:  2011-07-14       Impact factor: 6.860

3.  Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study.

Authors:  Haifa K Al-Ali; Nadja Jaekel; Christian Junghanss; Georg Maschmeyer; Rainer Krahl; Michael Cross; Gisa Hoppe; Dietger Niederwieser
Journal:  Leuk Lymphoma       Date:  2011-08-24

4.  Peroxisome proliferator-activated receptor gamma ligands stimulate myeloid differentiation and lipogenensis in human leukemia NB4 cells.

Authors:  Etsuko Yasugi; Akiko Horiuchi; Isao Uemura; Emiko Okuma; Masami Nakatsu; Kumiko Saeki; Yasushi Kamisaka; Hiroyuki Kagechika; Kazuki Yasuda; Akira Yuo
Journal:  Dev Growth Differ       Date:  2006-04       Impact factor: 2.053

5.  All-trans retinoic acid combined with 5-Aza-2'-deoxycitidine induces C/EBPα expression and growth inhibition in MLL-AF9-positive leukemic cells.

Authors:  Atsushi Fujiki; Toshihiko Imamura; Kenichi Sakamoto; Sachiko Kawashima; Hideki Yoshida; Yoshifumi Hirashima; Mitsuru Miyachi; Shigeki Yagyu; Takuya Nakatani; Kanji Sugita; Hajime Hosoi
Journal:  Biochem Biophys Res Commun       Date:  2012-10-10       Impact factor: 3.575

6.  5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.

Authors:  Sarah Ivanoff; Berengere Gruson; Sylvain P Chantepie; Emilie Lemasle; Lavinia Merlusca; Veronique Harrivel; Amandine Charbonnier; Patrick Votte; Bruno Royer; Jean-Pierre Marolleau
Journal:  Am J Hematol       Date:  2013-05-30       Impact factor: 10.047

7.  Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα.

Authors:  Hui Hui; Yan Chen; Hao Yang; Kai Zhao; Qian Wang; Li Zhao; Xiaotang Wang; Zhiyu Li; Na Lu; Qinglong Guo
Journal:  Int J Cancer       Date:  2013-09-03       Impact factor: 7.396

8.  Effects of PPARγ Ligands on Leukemia.

Authors:  Yoko Tabe; Marina Konopleva; Michael Andreeff; Akimichi Ohsaka
Journal:  PPAR Res       Date:  2012-05-21       Impact factor: 4.964

9.  Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment.

Authors:  Pamela S Becker
Journal:  ScientificWorldJournal       Date:  2012-01-04

Review 10.  Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas.

Authors:  Heng Sheng Sow; Stephen R Mattarollo
Journal:  Oncoimmunology       Date:  2013-11-05       Impact factor: 8.110
View more
  16 in total

Review 1.  Drug Repurposing by Tumor Tissue Editing.

Authors:  Florian Lüke; Dennis Christoph Harrer; Pan Pantziarka; Tobias Pukrop; Lina Ghibelli; Christopher Gerner; Albrecht Reichle; Daniel Heudobler
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

Review 2.  Potential role for all-trans retinoic acid in nonpromyelocytic acute myeloid leukemia.

Authors:  Hayley S Ma; Tara M Robinson; Donald Small
Journal:  Int J Hematol Oncol       Date:  2017-03-14

Review 3.  Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.

Authors:  Julia Stomper; John Charles Rotondo; Gabriele Greve; Michael Lübbert
Journal:  Leukemia       Date:  2021-05-06       Impact factor: 11.528

4.  Metronomics: Intrinsic Anakoinosis Modulator?

Authors:  André Nicolas; Manon Carré; Eddy Pasquier
Journal:  Front Pharmacol       Date:  2018-06-25       Impact factor: 5.810

Review 5.  Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue.

Authors:  Daniel Heudobler; Michael Rechenmacher; Florian Lüke; Martin Vogelhuber; Tobias Pukrop; Wolfgang Herr; Lina Ghibelli; Christopher Gerner; Albrecht Reichle
Journal:  Int J Mol Sci       Date:  2018-11-09       Impact factor: 5.923

6.  (Chalcogen)semicarbazones and their cobalt complexes differentiate HL-60 myeloid leukaemia cells and are cytotoxic towards tumor cell lines.

Authors:  Tamara R Todorović; Jelena Vukašinović; Gustavo Portalone; Sherif Suleiman; Nevenka Gligorijević; Snezana Bjelogrlić; Katarina Jovanović; Siniša Radulović; Katarina Anđelković; Analisse Cassar; Nenad R Filipović; Pierre Schembri-Wismayer
Journal:  Medchemcomm       Date:  2016-10-20       Impact factor: 3.597

7.  Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.

Authors:  Kelly J Norsworthy; Eunpi Cho; Jyoti Arora; Jeanne Kowalski; Hua-Ling Tsai; Erica Warlick; Margaret Showel; Keith W Pratz; Lesley A Sutherland; Steven D Gore; Anna Ferguson; Sarah Sakoian; Jackie Greer; Igor Espinoza-Delgado; Richard J Jones; William H Matsui; B Douglas Smith
Journal:  Leuk Res       Date:  2016-09-03       Impact factor: 3.156

8.  Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia.

Authors:  Christina Hart; Martin Vogelhuber; Daniel Wolff; Sebastian Klobuch; Lina Ghibelli; Jürgen Foell; Selim Corbacioglu; Klaus Rehe; Guy Haegeman; Simone Thomas; Wolfgang Herr; Albrecht Reichle
Journal:  Cancer Microenviron       Date:  2015-08-11

9.  Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML.

Authors:  Daniel Heudobler; Sebastian Klobuch; Simone Thomas; Joachim Hahn; Wolfgang Herr; Albrecht Reichle
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

10.  Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction.

Authors:  Emanuele Bruni; Albrecht Reichle; Manuel Scimeca; Elena Bonanno; Lina Ghibelli
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.